User login
Avène Hydrating Sunscreen Lotions
Pierre Fabre Dermo-Cosmétique USA introduces 5 Avène Hydrating Sunscreen Lotions with sun protection factor 50+. The Hydrating Sunscreen Lotion contains avobenzone, homosalate, octisalate, and octocrylene for broad-spectrum UVA and UVB protection on the face and body with a smooth finish. The Ultra-Light Hydrating Sunscreen Lotion is suitable for the face with a matte finish. The Ultra-Light Hydrating Sunscreen Lotion Spray is fast absorbing with a sheer finish for application on the body. The Mineral Hydrating Sunscreen Lotions are available in light and ultra-light formulations. They offer sheer, nonwhitening, broad-spectrum UVA and UVB protection with both titanium dioxide and zinc oxide. The light formulation is suitable for the face and body, and the ultra-light formulation is suitable for the face. All of the sunscreens are water resistant for 80 minutes of water activity and are formulated with vitamin E (tocopheryl acetate) to provide antioxidant protection and glycerin for long-lasting hydration. These sunscreens will be available mid-March 2015. For more information, visit www.aveneusa.com.
cosmelan
Mesoestetic introduces cosmelan for the correction of pigmentary imperfections on the skin. This topical treatment eliminates dark spots by affecting melanocytes, which inhibits melanin production in hyperpigmented areas. As a result, spots disappear or are noticeably lightened. Its formula has antioxidant properties to enhance the skin’s radiance and even out skin tone. The cosmelan pack includes an intense depigmenting mask (cosmelan 1) and an oil-removing solution for skin cleansing and exfoliation, both for use in the physician’s office. It also contains a depigmenting maintenance cream (cosmelan 2) and hydra-vital factor k moisturizing cream, both for at-home use. The treatment consists of 2 phases: 1 or 2 sessions at the physician’s office with cosmelan 1, followed by at-home treatment (cosmelan 2) for 6 to 9 months. cosmelan is suitable for all skin types. For more information, visit www.mesoestetic.com.
Cresemba
Astellas Pharma US, Inc, announces approval of the investigational once-daily intravenous and oral broad-spectrum Cresemba (isavuconazonium) by the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration. Cresemba is indicated for the treatment of invasive aspergillosis and invasive mucormycosis, both life-threatening fungal infections that predominately occur in immunocompromised patients. The review of the New Drug Application is expected to be completed in March 2015. For more information, visit www.astellas.us.
Glytone Lipid Recovery Cream
Pierre Fabre Dermo-Cosmétique USA introduces an enhanced Glytone Lipid Recovery Cream for use on inflamed and dry skin following cosmetic procedures such as chemical peels, lasers, microdermabrasion, and fillers. It contains camelina oil to preserve lipid barrier function; retinyl palmitate to repair damaged skin tissue; sodium hyaluronate to help skin cell proliferation and tissue repair; and shea butter, glycerin, and squalane to hydrate and moisturize. This postprocedure cream is now lighter in texture, allowing for faster absorption. Glytone Lipid Recovery Cream is physician dispensed. For more information, visit www.glytone-usa.com.
Opdivo
Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Opdivo (nivolumab) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. It works by inhibiting the PD-1 (programmed death receptor-1) protein on cells, which blocks the body’s immune system from attacking melanoma tumors. The indication represents accelerated approval based on tumor response rate and durability of response. For more information, visit www.opdivo.com.
Pazeo
Alcon, a Novartis company, receives US Food and Drug Administration approval of Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7% for daily ocular itch relief associated with allergic conjunctivitis. It is administered one drop in each affected eye once daily and was approved with efficacy data at 24 hours following a dose. Pazeo is anticipated to be available by prescription in the United States in March 2015. For more information, visit www.myalcon.com/products/pharmaceutical/pazeo.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Avène Hydrating Sunscreen Lotions
Pierre Fabre Dermo-Cosmétique USA introduces 5 Avène Hydrating Sunscreen Lotions with sun protection factor 50+. The Hydrating Sunscreen Lotion contains avobenzone, homosalate, octisalate, and octocrylene for broad-spectrum UVA and UVB protection on the face and body with a smooth finish. The Ultra-Light Hydrating Sunscreen Lotion is suitable for the face with a matte finish. The Ultra-Light Hydrating Sunscreen Lotion Spray is fast absorbing with a sheer finish for application on the body. The Mineral Hydrating Sunscreen Lotions are available in light and ultra-light formulations. They offer sheer, nonwhitening, broad-spectrum UVA and UVB protection with both titanium dioxide and zinc oxide. The light formulation is suitable for the face and body, and the ultra-light formulation is suitable for the face. All of the sunscreens are water resistant for 80 minutes of water activity and are formulated with vitamin E (tocopheryl acetate) to provide antioxidant protection and glycerin for long-lasting hydration. These sunscreens will be available mid-March 2015. For more information, visit www.aveneusa.com.
cosmelan
Mesoestetic introduces cosmelan for the correction of pigmentary imperfections on the skin. This topical treatment eliminates dark spots by affecting melanocytes, which inhibits melanin production in hyperpigmented areas. As a result, spots disappear or are noticeably lightened. Its formula has antioxidant properties to enhance the skin’s radiance and even out skin tone. The cosmelan pack includes an intense depigmenting mask (cosmelan 1) and an oil-removing solution for skin cleansing and exfoliation, both for use in the physician’s office. It also contains a depigmenting maintenance cream (cosmelan 2) and hydra-vital factor k moisturizing cream, both for at-home use. The treatment consists of 2 phases: 1 or 2 sessions at the physician’s office with cosmelan 1, followed by at-home treatment (cosmelan 2) for 6 to 9 months. cosmelan is suitable for all skin types. For more information, visit www.mesoestetic.com.
Cresemba
Astellas Pharma US, Inc, announces approval of the investigational once-daily intravenous and oral broad-spectrum Cresemba (isavuconazonium) by the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration. Cresemba is indicated for the treatment of invasive aspergillosis and invasive mucormycosis, both life-threatening fungal infections that predominately occur in immunocompromised patients. The review of the New Drug Application is expected to be completed in March 2015. For more information, visit www.astellas.us.
Glytone Lipid Recovery Cream
Pierre Fabre Dermo-Cosmétique USA introduces an enhanced Glytone Lipid Recovery Cream for use on inflamed and dry skin following cosmetic procedures such as chemical peels, lasers, microdermabrasion, and fillers. It contains camelina oil to preserve lipid barrier function; retinyl palmitate to repair damaged skin tissue; sodium hyaluronate to help skin cell proliferation and tissue repair; and shea butter, glycerin, and squalane to hydrate and moisturize. This postprocedure cream is now lighter in texture, allowing for faster absorption. Glytone Lipid Recovery Cream is physician dispensed. For more information, visit www.glytone-usa.com.
Opdivo
Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Opdivo (nivolumab) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. It works by inhibiting the PD-1 (programmed death receptor-1) protein on cells, which blocks the body’s immune system from attacking melanoma tumors. The indication represents accelerated approval based on tumor response rate and durability of response. For more information, visit www.opdivo.com.
Pazeo
Alcon, a Novartis company, receives US Food and Drug Administration approval of Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7% for daily ocular itch relief associated with allergic conjunctivitis. It is administered one drop in each affected eye once daily and was approved with efficacy data at 24 hours following a dose. Pazeo is anticipated to be available by prescription in the United States in March 2015. For more information, visit www.myalcon.com/products/pharmaceutical/pazeo.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
Avène Hydrating Sunscreen Lotions
Pierre Fabre Dermo-Cosmétique USA introduces 5 Avène Hydrating Sunscreen Lotions with sun protection factor 50+. The Hydrating Sunscreen Lotion contains avobenzone, homosalate, octisalate, and octocrylene for broad-spectrum UVA and UVB protection on the face and body with a smooth finish. The Ultra-Light Hydrating Sunscreen Lotion is suitable for the face with a matte finish. The Ultra-Light Hydrating Sunscreen Lotion Spray is fast absorbing with a sheer finish for application on the body. The Mineral Hydrating Sunscreen Lotions are available in light and ultra-light formulations. They offer sheer, nonwhitening, broad-spectrum UVA and UVB protection with both titanium dioxide and zinc oxide. The light formulation is suitable for the face and body, and the ultra-light formulation is suitable for the face. All of the sunscreens are water resistant for 80 minutes of water activity and are formulated with vitamin E (tocopheryl acetate) to provide antioxidant protection and glycerin for long-lasting hydration. These sunscreens will be available mid-March 2015. For more information, visit www.aveneusa.com.
cosmelan
Mesoestetic introduces cosmelan for the correction of pigmentary imperfections on the skin. This topical treatment eliminates dark spots by affecting melanocytes, which inhibits melanin production in hyperpigmented areas. As a result, spots disappear or are noticeably lightened. Its formula has antioxidant properties to enhance the skin’s radiance and even out skin tone. The cosmelan pack includes an intense depigmenting mask (cosmelan 1) and an oil-removing solution for skin cleansing and exfoliation, both for use in the physician’s office. It also contains a depigmenting maintenance cream (cosmelan 2) and hydra-vital factor k moisturizing cream, both for at-home use. The treatment consists of 2 phases: 1 or 2 sessions at the physician’s office with cosmelan 1, followed by at-home treatment (cosmelan 2) for 6 to 9 months. cosmelan is suitable for all skin types. For more information, visit www.mesoestetic.com.
Cresemba
Astellas Pharma US, Inc, announces approval of the investigational once-daily intravenous and oral broad-spectrum Cresemba (isavuconazonium) by the Anti-infective Drugs Advisory Committee of the US Food and Drug Administration. Cresemba is indicated for the treatment of invasive aspergillosis and invasive mucormycosis, both life-threatening fungal infections that predominately occur in immunocompromised patients. The review of the New Drug Application is expected to be completed in March 2015. For more information, visit www.astellas.us.
Glytone Lipid Recovery Cream
Pierre Fabre Dermo-Cosmétique USA introduces an enhanced Glytone Lipid Recovery Cream for use on inflamed and dry skin following cosmetic procedures such as chemical peels, lasers, microdermabrasion, and fillers. It contains camelina oil to preserve lipid barrier function; retinyl palmitate to repair damaged skin tissue; sodium hyaluronate to help skin cell proliferation and tissue repair; and shea butter, glycerin, and squalane to hydrate and moisturize. This postprocedure cream is now lighter in texture, allowing for faster absorption. Glytone Lipid Recovery Cream is physician dispensed. For more information, visit www.glytone-usa.com.
Opdivo
Bristol-Myers Squibb Company announces US Food and Drug Administration approval of Opdivo (nivolumab) for the treatment of patients with unresectable or metastatic melanoma and disease progression following ipilimumab and, if BRAF V600 mutation positive, a BRAF inhibitor. It works by inhibiting the PD-1 (programmed death receptor-1) protein on cells, which blocks the body’s immune system from attacking melanoma tumors. The indication represents accelerated approval based on tumor response rate and durability of response. For more information, visit www.opdivo.com.
Pazeo
Alcon, a Novartis company, receives US Food and Drug Administration approval of Pazeo (olopatadine hydrochloride ophthalmic solution) 0.7% for daily ocular itch relief associated with allergic conjunctivitis. It is administered one drop in each affected eye once daily and was approved with efficacy data at 24 hours following a dose. Pazeo is anticipated to be available by prescription in the United States in March 2015. For more information, visit www.myalcon.com/products/pharmaceutical/pazeo.
If you would like your product included in Product News, please e-mail a press release to the Editorial Office at cutis@frontlinemedcom.com.
